Indian Biotechnology firm Transgene Biotek has received patent in United States for its novel molecule to be developed for treatment of liver cancer. "This granting of a USA patent is a significant step in moving ahead with the development of this novel drug," Transgene Biotek said in a filing to the BSE.
The company's novel molecule miRNA 101 for therapy against Liver cancer has been allowed for issuance of a USA patent after the prosecution on merits have been closed, it added. Hepato-cellular Cancer is the most common primarily liver cancer, accounting to roughly 90 per cent of this class of malignancy, with poor prognosis due to its ability to rapidly spread, Transgene Biotek said.
The company's current product portfolio covers segments like Oncology, Auto-immunity, drug delivery and bio-generics.
The company's novel molecule miRNA 101 for therapy against liver
The company's novel molecule miRNA 101 for therapy against liver
